US 7,320,793 B2 | ||
Molecular antigen array | ||
Wolfgang A Renner, Zurich (Switzerland); Martin Bachmann, Winterthur (Switzerland); Alain Tissot, Zurich (Switzerland); Patrick Maurer, Winterthur (Switzerland); Franziska Lechner, Zurich (Switzerland); Peter Sebbel, Zurich (Switzerland); Christine Piossek, Winterthur (Switzerland); Rainer Ortmann, Saint Louis (France); Rainer Luond, Therwil (Switzerland); Matthias Staufenbiel, Lorrach (Germany); and Peter Frey, Bern (Switzerland) | ||
Assigned to Cytos Biotechnology AG, Zürich-Schlieren (Switzerland); and Novartis Pharma AG, Basel (Switzerland) | ||
Filed on Jan. 18, 2002, as Appl. No. 10/50,898. | ||
Claims priority of provisional application 60/331045, filed on Nov. 07, 2001. | ||
Claims priority of provisional application 60/326998, filed on Oct. 05, 2001. | ||
Claims priority of provisional application 60/288549, filed on May 04, 2001. | ||
Claims priority of provisional application 60/262379, filed on Jan. 19, 2001. | ||
Prior Publication US 2003/0175711 A1, Sep. 18, 2003 | ||
This patent is subject to a terminal disclaimer. | ||
Int. Cl. A61K 39/385 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 47/30 (2006.01) |
U.S. Cl. 424—158.1 [424/400; 424/192.1; 424/193.1; 424/194.1; 424/195.11; 424/196.11; 424/198.1; 424/278.1; 424/281.1; 424/282.1] | 52 Claims |
1. A composition comprising:
(a) a non-natural molecular scaffold comprising:
(i) a core particle that is a virus-like particle of an RNA bacteriophage; and
(ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle
by at least one covalent bond;
(b) an antigen or antigenic determinant with at least one second attachment site,
wherein said antigen or antigenic determinant is amyloid beta peptide (Aβ1-42) or a fragment thereof, and wherein said second attachment site is selected from the group consisting of:
(i) an attachment site not naturally occurring with said antigen or antigenic determinant; and
(ii) an attachment site naturally occurring with said antigen or antigenic determinant, wherein said second attachment site associates with said first attachment site through at least one non-peptide bond; andwherein said antigen or antigenic determinant and said non-natural molecular scaffold interact through said association to
form an ordered and repetitive antigen array.
|